Literature DB >> 7658719

Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells.

M J Stewart1, S Litz-Jackson, G S Burgess, E A Williamson, D S Leibowitz, H S Boswell.   

Abstract

Experiments were performed to elucidate the mechanism through which p210 BCR-ABL, by its downstream signals, regulates c-myc messenger RNA expression in hematopoietic cells. We studied a model system in which stable expression of p210 BCR-ABL in interleukin-3 (IL-3) dependent murine myeloid cell lines led to growth factor independent transformation. Active c-myc transcription was observed in p210 BCR-ABL transformed cells by nuclear run-on assay, and in heterologous reporter assays performed with the 5' regulatory region of murine c-myc linked to firefly luciferase. Transcription initiation occurred primarily from the P2 promoter in p210 BCR-ABL transformed cells. Cis and trans elements responsible for transcription initiation from the c-myc P2 promoter were studied. Expression of E2F1 protein in p210 BCR-ABL transformed cells accounted, in part, for binding to the E2F site of the P2 c-myc promoter. The functional importance of E2F1 expression in p210 BCR-ABL transformed cells toward c-myc transcription was established in reporter assays performed with the P2 c-myc promoter containing either wild-type or mutant E2F sites. Mutation of the E2F motif of P2 5' c-myc reduced activity of the promoter by 50%. By gel mobility shift, E2F1 was found in P2 c-myc band shift complexes along with the cyclin-dependent kinase 2. Therefore, coupling of E2F to components of the retinoblastoma-cyclin pathway defines a route from p210 BCR-ABL to c-myc transcription, which is required for p210 BCR-ABL transformation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658719

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  13 in total

1.  hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival.

Authors:  Francesca Pellicano; Laura Park; Lisa E M Hopcroft; Mansi M Shah; Lorna Jackson; Mary T Scott; Cassie J Clarke; Amy Sinclair; Sheela A Abraham; Alan Hair; G Vignir Helgason; Mark Aspinall-O'Dea; Ravi Bhatia; Gustavo Leone; Kamil R Kranc; Anthony D Whetton; Tessa L Holyoake
Journal:  Blood       Date:  2018-02-05       Impact factor: 22.113

2.  Inhibition of DLX-7 homeobox gene causes decreased expression of GATA-1 and c-myc genes and apoptosis.

Authors:  T Shimamoto; S Nakamura; J Bollekens; F H Ruddle; K Takeshita
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

3.  BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis.

Authors:  M Sattler; S Verma; C H Byrne; G Shrikhande; T Winkler; P A Algate; L R Rohrschneider; J D Griffin
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

4.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

5.  Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.

Authors:  Anna M Eiring; Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Ji Suk Chang; Mario Notari; William Willis; Carlo Gambacorti-Passerini; Stefano Volinia; Guido Marcucci; Michael A Caligiuri; Gustavo W Leone; Danilo Perrotti
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

6.  Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas.

Authors:  Michael W Harr; Timothy G Graves; Erin L Crawford; Kristy A Warner; Cheryl A M Reed; James C Willey
Journal:  Mol Cancer       Date:  2005-07-13       Impact factor: 27.401

7.  BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.

Authors:  Nitesh Sharma; Vera Magistroni; Rocco Piazza; Stefania Citterio; Caterina Mezzatesta; Praveen Khandelwal; Alessandra Pirola; Carlo Gambacorti-Passerini
Journal:  Mol Cancer       Date:  2015-07-16       Impact factor: 27.401

8.  Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.

Authors:  Zheng Hu; Xiao-Fen Pan; Fu-Qun Wu; Li-Yuan Ma; Da-Peng Liu; Ying Liu; Ting-Ting Feng; Fan-Yi Meng; Xiao-Li Liu; Qian-Li Jiang; Xiao-Qin Chen; Jing-Lei Liu; Ping Liu; Zhu Chen; Sai-Juan Chen; Guang-Biao Zhou
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

9.  MCTS1 promotes the development of lung adenocarcinoma by regulating E2F1 expression.

Authors:  Cun Gao; Rui Dong; Yongmeng Li; Jinghui Liang; Hui Tian
Journal:  Oncol Lett       Date:  2021-05-17       Impact factor: 2.967

10.  STAT3 is required for the gp130-mediated full activation of the c-myc gene.

Authors:  N Kiuchi; K Nakajima; M Ichiba; T Fukada; M Narimatsu; K Mizuno; M Hibi; T Hirano
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.